左、右半结肠癌的药物治疗现状及展望

被引：5

作者：

王晰程

韦青

沈琳

机构：

[1] 北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科恶性肿瘤发病机制及转化研究教育部重点实验室

来源：

中国医学前沿杂志(电子版) | 2017年 / 9卷 / 01期

关键词：

结肠癌; EGFR单抗; 靶向治疗; 免疫治疗;

D O I：

暂无

中图分类号：

R735.35 [];

学科分类号：

100214 ;

摘要：

目前,越来越多的证据提示左、右半结肠癌是预后截然不同的疾病。就药物治疗而言,RAS野生型的左半结肠癌更有可能从表皮生长因子受体(epidermal growth factor receptor,EGFR)单抗治疗中获益,而右半结肠癌无论对标准化疗还是联合靶向治疗均不太敏感。但是,除了RAS基因状态及原发灶部位,如何进一步富集EGFR单抗治疗获益人群呢?近期研究显示BRAF突变、HER2扩增、EGFR配体低表达是EGFR单抗治疗的负性预测因素,而本身治疗效果不佳的右半结肠癌患者该如何改善预后?由于右半结肠癌微卫星不稳定比例高,BRAF突变及RAS突变率较高,所以未来我们可能还要依赖于这些特殊的分子靶点或联合多种治疗手段来提高疗效。

引用

页码：59 / 64

页数：6

共 14 条

[1]

人表皮生长因子受体2在直肠癌手术切除标本与活检标本表达的一致性研究.[J].王晰程;孙宇;高静;郑建萍;沈琳;.中华胃肠外科杂志.2015, 06

[2] Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab [J].

Santin, Alessandro D. ;

Bellone, Stefania ;

Buza, Natalia ;

Choi, Jungmin ;

Schwartz, Peter E. ;

Schlessinger, Joseph ;

Lifton, Richard P. .

CLINICAL CANCER RESEARCH, 2016, 22 (23) :5682-5687

[3] Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy [J].

Johanns, Tanner M. ;

Miller, Christopher A. ;

Dorward, Ian G. ;

Tsien, Christina ;

Chang, Edward ;

Perry, Arie ;

Uppaluri, Ravindra ;

Ferguson, Cole ;

Schmidt, Robert E. ;

Dahiya, Sonika ;

Ansstas, George ;

Mardis, Elaine R. ;

Dunn, Gavin P. .

CANCER DISCOVERY, 2016, 6 (11) :1230-1236

[4] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade [J].

Ebert, Peter J. R. ;

Cheung, Jeanne ;

Yang, Yagai ;

McNamara, Erin ;

Hong, Rebecca ;

Moskalenko, Marina ;

Gould, Stephen E. ;

Maecker, Heather ;

Irving, Bryan A. ;

Kim, Jeong M. ;

Belvin, Marcia ;

Mellman, Ira .

IMMUNITY, 2016, 44 (03) :609-621

[5] HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials [J].

Richman, Susan D. ;

Southward, Katie ;

Chambers, Philip ;

Cross, Debra ;

Barrett, Jennifer ;

Hemmings, Gemma ;

Taylor, Morag ;

Wood, Henry ;

Hutchins, Gordon ;

Foster, Joseph M. ;

Oumie, Assa ;

Spink, Karen G. ;

Brown, Sarah R. ;

Jones, Marc ;

Kerr, David ;

Handley, Kelly ;

Gray, Richard ;

Seymour, Matthew ;

Quirke, Philip .

JOURNAL OF PATHOLOGY, 2016, 238 (04) :562-570

[6] A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility [J].

Vecchione, Loredana ;

Gambino, Valentina ;

Raaijmakers, Jonne ;

Schlicker, Andreas ;

Fumagalli, Arianna ;

Russo, Mariangela ;

Villanueva, Alberto ;

Beerling, Evelyne ;

Bartolini, Alice ;

Mollevi, David G. ;

El-Murr, Nizar ;

Chiron, Marielle ;

Calvet, Loreley ;

Nicolazzi, Celine ;

Combeau, Cecile ;

Henry, Christophe ;

Simon, Iris M. ;

Tian, Sun ;

in't Veld, Sjors ;

D'ario, Giovanni ;

Mainardi, Sara ;

Beijersbergen, Roderick L. ;

Lieftink, Cor ;

Linn, Sabine ;

Rumpf-Kienzl, Cornelia ;

Delorenzi, Mauro ;

Wessels, Lodewyk ;

Salazar, Ramon ;

Di Nicolantonio, Federica ;

Bardelli, Alberto ;

van Rheenen, Jacco ;

Medema, Rene H. ;

Tejpar, Sabine ;

Bernards, Rene .

CELL, 2016, 165 (02) :317-330

[7] Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas [J].

Leto, Simonetta M. ;

Sassi, Francesco ;

Catalano, Irene ;

Torri, Valter ;

Migliardi, Giorgia ;

Zanella, Eugenia R. ;

Throsby, Mark ;

Bertotti, Andrea ;

Trusolino, Livio .

CLINICAL CANCER RESEARCH, 2015, 21 (24) :5519-5531

[8] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study [J].

Cremolini, Chiara ;

Loupakis, Fotios ;

Antoniotti, Carlotta ;

Lupi, Cristiana ;

Sensi, Elisa ;

Lonardi, Sara ;

Mezi, Silvia ;

Tomasello, Gianluca ;

Ronzoni, Monica ;

Zaniboni, Alberto ;

Tonini, Giuseppe ;

Carlomagno, Chiara ;

Allegrini, Giacomo ;

Chiara, Silvana ;

D'Amico, Mauro ;

Granetto, Cristina ;

Cazzaniga, Marina ;

Boni, Luca ;

Fontanini, Gabriella ;

Falcone, Alfredo .

LANCET ONCOLOGY, 2015, 16 (13) :1306-1315

[9]

Immunogenic Cell Death in Cancer Therapy.[J].Guido Kroemer;Lorenzo Galluzzi;Oliver Kepp;Laurence Zitvogel.Annual Review of Immunology.2013, 1

[10] Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo [J].

Yasuda, S. ;

Sho, M. ;

Yamato, I. ;

Yoshiji, H. ;

Wakatsuki, K. ;

Nishiwada, S. ;

Yagita, H. ;

Nakajima, Y. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 172 (03) :500-506

← 1 2 →